AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06754631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent Nebulization of Salbutamol
Description: were treated with intermittent nebulization of salbutamol at a dose of 0.15 mg/kg/dose, administered through a face mask with an oxygen flow rate of 6-8 L per minute. They Children received at least 2-3 nebulizations and no more than 7.5 mg/dose every 30 minutes for 4 hours.
Study NCT06751186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teté Dance Guided Support
Description: A culturally tailored behavioral intervention combining physical activity and community engagement to support breastfeeding practices.
Study NCT06755918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Children will be monitored when fowler is in position during the use of nebulizers. In the Fowler position, the drug will be drained into the nebulizer chamber. Mask and nebulizer connections will be completed. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. Routine nursing care is applied during the use of nebulizer. During the use of a control group nebulizer, routine nebulizer will be used without video game and mask painting. After the receipt of the receipt, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
Study NCT06755918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game
Description: Children will be monitoring while the fowler position during the use of nebulizers. While the Fowler position is in the position of the drug, the drug will be drained into the nebulizer reservoir. The nebul mask will be attached to cover the mouth and nose. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. At the same time, the Water-Sorting Game will be introduced while the use of nebul will be introduced and you will be asked to play. After the receipt of the receipt, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
Study NCT06755918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mask painting
Description: While the Fowler position is in the position of the drug, the drug will be drained into the nebulizer reservoir. The nebul mask will be attached to cover the mouth and nose. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. At the same time, mask painting process will be introduced while the use of nebul continues. For mask painting, six color paint will be given and the shapes and colors will be completely left to the child by leaving it to him. After the mask painting and receipt is finished, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
Study NCT06756048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal Nerve Block
Description: Following standard ASA monitoring, patients were positioned on the surgical table with their backs facing the operator. Skin antisepsis was achieved using povidone. A high-frequency 8-18 MHz linear ultrasound probe was used.~After palpating the rhomboid muscles and intercostal spaces at the T6-T7 levels, the medial border of the scapula and the vertebral column were identified. The ultrasound probe was placed horizontally along the medial border of the scapula. Using ultrasound guidance, the ribs, rhomboid muscles, intercostal muscles, and pleura were visualized. Once these anatomical structures were clearly identified, a 50 mm, 22G regional block needle was advanced in-plane from caudal to cranial under ultrasound guidance until the interfascial plane beneath the rhomboid muscles was reached and total of 20 ml of 0.25% bupivacaine (Marcaine® 0.5%, AstraZeneca PLC, London, UK) was injected.
Study NCT06756022 — intervention group
Intervention type: DRUG
Intervention: Dolasetron mesylate injection
Description: 1.8 mg/kg Dolasetron mesylate injection should be injected intravenously 30±10 min before chemotherapy infusion, with the maximum dose not exceeding 100 mg. It can also be mixed with apple juice or apple-grape juice for oral use, the oral dose is 1.8 mg/kg, the maximum amount is not more than 100 mg, taken orally within 1 h before chemotherapy.~Other antiemetic drugs, except dolasetron, are at the discretion of the subject's supervising physician in accordance with clinical practice.
Study NCT06753383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To the Virtual Reality Based Exercise
Description: After posterior fusion surgery, a rehabilitation program will be applied to individuals with AIS using Kinect Sports Ultimate for 30 minutes per day for a total of 6 weeks, 2 days a week.
Study NCT06753383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy and rehabilitation program
Description: 14 patients with posterior fusion AIS routinely in the postoperative clinic for 6 weeks. the physiotherapy program used will be applied.
Study NCT06752083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: AHCC® (Active Hexose Correlated Compound)
Description: 3 capsules of AHCC® daily for 4-6 months to support immune modulation and promote HPV negativity.
Study NCT06752083 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gardasil 9®
Description: Administration of the nonavalent HPV vaccine to provide protection against high-risk HPV genotypes.
Study NCT06754397 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Cholangiopancreatography
Description: Three most important sequences included axial T2 weighted scan from liver to ampullary region followed by T2 weighted 3D FSE sequence acquired in coronal oblique plane using respiratory triggering by tying bellows over abdomen. After this breath hold HASTE sequence is acquired in coronal plane. Maximum intensity projection (MIP) and thick slab images are also used for interpretation. US, CECT and MRCP scans are interpreted by radiologists blinded to other imaging findings
Study NCT06524791 — intervention group
Intervention type: OTHER
Intervention: bacteriophage detection
Description: bacteriophage detection
Study NCT04711629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Tests
Description: Respiratory function test, arterial blood gas analysis, six-minute walking test (6-MWT), mMRC Dyspnea Scale, St George Quality of Life Questionnaire and Hospital Anxiety Depression Scale
Study NCT04711629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Tests
Description: Respiratory function test, arterial blood gas analysis, six-minute walking test (6-MWT), mMRC Dyspnea Scale, St George Quality of Life Questionnaire and Hospital Anxiety Depression Scale
Study NCT06754111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ideal birth environment
Description: ideal birth room While designing a single room without unnecessary medical equipment, your own bed linen, bed linen, It will be a pillow case, a photo frame, he will be able to listen to the music he wants, he will be able to make a photo of his own choice.~There will be a companion, a birthing ball and chair, and the room will allow freedom of movement.~It will be designed to allow
Study NCT06751953 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional third-line therapy
Description: Conventional third-line therapy includes oral chemotherapy drugs and/or targeted cancer drugs. The medication, dosage and treatment cycle of oral chemotherapy drugs and/or targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances.
Study NCT06751953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-loaded DC vaccine
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study NCT06752590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1110
Description: ONO-1110 tablets once a day
Study NCT06752590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study NCT06755593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: We use acupuncture needles of size 0.30 \* 25 mm and electroacupuncture machine KWD808-1 manufactured by Gujin Greatwall (Frequency 100Hz)
Study NCT06755593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: We use acupuncture needles of size 0.30 \* 25 mm and electroacupuncture machine KWD808-1 manufactured by Gujin Greatwall (Frequency 100Hz)
Study NCT06755593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous laser
Description: We use intravenous laser with the iBIO-ILIB He-Ne laser device Mini-630 with 635 nm wavelength manufactured by Vietnam Laser Technology Center.
Study NCT06755762 — intervention group
Intervention type: OTHER
Intervention: Organoid 3D culture
Description: Investigate different normal cells (lung, bone, soft tissue, liver, etc) as metastatic organs to simulate the behaviors of CTCs in metastatic sites
Study NCT06753513 — intervention group
Intervention type: OTHER
Intervention: 99mTc-FDPH46 SPECT/CT Imaging
Description: 99mTc-FDPH46 SPECT/CT Imaging
Study NCT06753812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: constraint induced movement therapy
Description: Children in this group will receive constraint induced movement therapy for 10 sessions over 2 weeks, each session lasting 90 minutes, in addition to the treatment they receive 2 days a week at the special education and rehabilitation centers they attend.
Study NCT06753812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control (Standard treatment)
Description: Children in this group will continue to receive their treatment at the special education and rehabilitation center they attend, two days a week for 40 minutes.
Study NCT06751901 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-based peptide vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
Study NCT06751901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
Study NCT06751901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-based peptide vaccine
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study NCT06752512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: 24/7 remote patient monitoring with a wearable thermometer
Study NCT06754306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal diet (100% energy)
Description: Daily intake of 100% energy requirements, adjusted individually based on each participant's basal metabolic rate (BMR).
Study NCT06754306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16+8 time-restricted eating group (100% energy)
Description: Participants will consume 100% energy within an 8-hour eating window and fast for the remaining 16 hours.
Study NCT06754306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16+8 time-restricted eating group (75% energy)
Description: Participants will consume 75% of their energy requirements within the 8-hour eating window.
Study NCT02860559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBX-1400
Description: Hematopoietic stem cells transplantation
Study NCT05159778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
Study NCT05159778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
Study NCT05173259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: F
Description: The participant will be asked to chew the two-coloured chewing gum naturally.
Study NCT06754306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate-day fasting group (75% energy)
Description: Participants alternate between feeding days (125% energy requirements) and fasting days (25% energy requirements).
Study NCT06754306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5+2 intermittent fasting group (75% energy)
Description: Participants consume 95% energy requirements for 5 consecutive days and 25% energy requirements for 2 fasting days.
Study NCT05173259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: The participant will be asked to chew the two-coloured chewing gum on the right-side.
Study NCT05173259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: L
Description: The participant will be asked to chew the two-coloured chewing gum on the left-side.
Study NCT06754306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-calorie diet group (75% energy)
Description: Participants will reduce daily caloric intake to 75% of energy requirements, consumed evenly across three meals.
Study NCT06754306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low-calorie diet group (45% energy)
Description: Participants will reduce daily caloric intake to 45% of energy requirements (\~800 kcal/day)
Study NCT06753552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Underwater US
Description: 7 min per session with an intensity of 0.9 W/cm2 for 20 sessions
Study NCT06753552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Underwater US
Description: 7 min per session with an intensity of 0.9 W/cm2 for 20 sessions
Study NCT06753552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CFO
Description: Custom made orthotics
Study NCT06295952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.
Study NCT06295952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF-36 and HADS
Description: Baseline assessment will be conducted within 30 days of starting treatment, week 12, 24 and week 28.
Study NCT06755801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevibolol
Description: Beta-blockers are the first-line treatment for patients with stable angina secondary to classic epicardial atherosclerotic disease, where their clinical benefits are well-established (4). However, their efficacy has not yet been demonstrated in ANOCA patients with MVD, where beta-blockers are frequently used due to their physiological plausibility. Beta-blockers act by competitively inhibiting catecholamine receptors. The therapeutic benefits of beta-blockade in patients with stable angina are mediated by a reduction in myocardial oxygen demand. Myocardial oxygen demand depends on heart rate, contractility, and left ventricular wall tension, all of which are reduced with beta-adrenergic blockade. The reduction in wall tension is partly mediated by the antihypertensive action of these drugs. The decrease in heart rate occurs both at rest and during sympathetic activation such as exercise or stress. The negative inotropic effect of these drugs also contributes to reducing myocardial oxyg
Study NCT06755801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06754358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LenSx
Description: Participants undergo FLACS using LenSx femtosecond laser system
Study NCT06754358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Z8
Description: Participants undergo FLACS using Z8 femtosecond laser system
Study NCT05757219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
Study NCT05757219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR) T-cell therapy
Description: Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
Study NCT04514341 — intervention group
Intervention type: OTHER
Intervention: Short Message Service (SMS)
Description: Patients with FIT orders receive seven messages over 60 days to remind them to return their kits for testing. Patients with colonoscopy orders receive eight messages to remind them to schedule an appointment for a colonoscopy over 90 days. After confirming their colonoscopy appointment, the patient gets educational messages on bowel preparation.
Study NCT04514341 — intervention group
Intervention type: OTHER
Intervention: Remote Patient Navigation
Description: Patient navigators at our partner FQHCs called patients who received a screening order for more than 60 days but failed to complete it or who had a positive stool-based test and needed a follow-up diagnostic colonoscopy.
Study NCT04573881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HistoSonics System
Description: The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
Study NCT06431503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tok-Sen Massage
Description: Press the wedge and tapping: the strength for pressing the wedge is 1000g±50g, the height for mallet free fall(instead of beating by arm)10cm±2cm. For Pressure massage, the strength for pressing the wedge is 1500g±50g.
Study NCT06431503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Massage
Description: Press the wedge: the strength for pressing the wedge is 1500g±50g,
Study NCT05696899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents
Description: A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
Study NCT04729816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food.
Description: Phase 1: Participants will be provided with a high fat/low fiber diet in the form of packed out meals and snacks for 10 days in total (days 2-11 and days 54-63)~Phase 2: Participants will be provided with the high fat/low fiber diet, plus 1 daily fiber-blend snack serving from days 12-25~Phase 3: Participants will receive 2 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 26-39.~Phase 4: Participants will receive 3 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 40-53.~Phase 5: Participants will return to the unsupplemented high fat/low fiber diet for days 54-63